Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1502-1512

  Chen, Yu Zhe ^a   Ruan, Gui Xin ^a   Yao, Xing Lei ^a   Li, Li Ming ^a   Hu, Ying ^b   Tabata, Yasuhiko ^c   Gao, Jian Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PHARMACEUTICAL COLLEGE   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

CCR7; dendritic cell; gene delivery; immunotherapy; spermine dextran

Indexed keywords

CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; DEXTRAN; GLYCOPROTEIN GP 100; PLASMID DNA; SPERMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER PREVENTION; CELL ENGINEERING; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA BINDING; DRUG SAFETY; GENETIC CODE; GENETIC ENGINEERING; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MALE; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL MOVEMENT; DENDRITIC CELLS; DEXTRANS; DNA; ENDOCYTOSIS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GP100 MELANOMA ANTIGEN; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECEPTORS, CCR7; SPERMINE; TRANSFECTION;

EID: 84877785185     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0985-8     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
2. Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res. 2006;95:115-45.
3. Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U. Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother. 2006;29(5):472-6.
4. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008;15(1):39-50.
5. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
6. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med. 1990;172(2):631-40.
7. Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK. Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol. 2003;13(6):439-47.
8. Rughetti A, Biffoni M, Sabbatucci M, Rahimi H, Pellicciotta I, Fattorossi A, et al. Transfected human dendritic cells to induce antitumor immunity. Gene Ther. 2000;7(17):1458-66.
9. Zhang X, Gordon JR, Xiang J. Advances in dendritic cell-based vaccine of cancer. Cancer Biother Radiopharm. 2002;17(6):601-19.
10. Srinivas R, Garu A, Moku G, Agawane SB, Chaudhuri A. A long-lasting dendritic cell DNA vaccination system using lysinylated amphiphiles with mannose-mimicking head-groups. Biomaterials. 2012;33(26):6220-9.
11. Markov OO, Mironova NL, Maslov MA, Petukhov IA, Morozova NG, Vlassov VV, et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J Control Release. 2012;160(2):200-10.
12. Suzuki R, Oda Y, Utoguchi N, Namai E, Taira Y, Okada N, et al. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release. 2009;133(3):198-205.
13. Chen YZ, Yao XL, Tabata Y, Nakagawa S, Gao JQ. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Clin Dev Immunol. 2010;2010:565643.
14. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617-28.
15. Un K, Kawakami S, Suzuki R, Maruyama K, Yamashita F, Hashida M. Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure. Hum Gene Ther. 2010;21(1):65-74.
16. Yoshida M, Jo J, Tabata Y. Augmented anti-tumor effect of dendritic cells genetically engineered by interleukin-12 plasmid DNA. J Biomater Sci Polym Ed. 2010;21(5):659-75.
17. Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther. 2009;20(10):1106-18.
18. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8(5):362-71.
19. Okada N, Mori N, Koretomo R, Okada Y, Nakayama T, Yoshie O, et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005;12(2):129-39.
20. Hosseinkhani H, Azzam T, Tabata Y, Domb AJ. Dextran-spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection. Gene Ther. 2004;11(2):194-203.
21. Okada N, Masunaga Y, Okada Y, Mizuguchi H, Iiyama S, Mori N, et al. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 2003;10(22):1891-902.
22. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77-92.
23. Rivas-Caicedo A, Soldevila G, Fortoul TI, Castell-Rodriguez A, Flores-Romo L, Garcia-Zepeda EA. Jak3 is involved in dendritic cell maturation and CCR7-dependent migration. PLoS One. 2009;4(9):e7066.
24. Kee SH, Cho EJ, Song JW, Park KS, Baek LJ, Song KJ. Effects of endocytosis inhibitory drugs on rubella virus entry into VeroE6 cells. Microbiol Immunol. 2004;48(11):823-9.
25. Walsh M, Tangney M, O'Neill MJ, Larkin JO, Soden DM, McKenna SL, et al. Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-l-lysine compacted DNA: implications for cancer gene therapy. Mol Pharm. 2006;3(6):644-53.
26. Benard A, Boue J, Chapey E, Jaume M, Gomes B, Dietrich G. Delta opioid receptors mediate chemotaxis in bone marrow-derived dendritic cells. J Neuroimmunol. 2008;197(1):21-8.
27. Nagane K, Jo J, Tabata Y. Promoted adipogenesis of rat mesenchymal stem cells by transfection of small interfering RNA complexed with a cationized dextran. Tissue Eng Part A. 2010;16(1):21-31.
28. Jo J, Nagaya N, Miyahara Y, Kataoka M, Harada-Shiba M, Kangawa K, et al. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. Tissue Eng. 2007;13(2):313-22.
29. Zhang ZM, Zhang FH, Wang XM, Zhang C, Liu J, Gu LM, et al. Enhanced expression of CD40L cDNA on ovarian cancer cell line OVHM induces the secretion of Th1 cytokines from dendritic cells. Zhonghua Zhong Liu Za Zhi. 2008;30(3):174-8.
30. Peng P, Shen K, He W, Wu M, Wei W, Lang JH, et al. Primary study on fusions of ovarian carcinoma cells to dendritic cell transfected with interleukin-12 gene in vitro. Zhonghua Fu Chan Ke Za Zhi. 2006;41(1):57-61.
31. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37-44.
32. Gumbleton M, Abulrob AG, Campbell L. Caveolae: an alternative membrane transport compartment. Pharm Res. 2000;17(9):1035-48.
33. Silva W, Maldonado H, Chompre G, Mayol N. Caveolae a new subcellular transport organelle. Bol Asoc Med P R. 1998;90(1-3):30-3.
34. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994;91(14):6458-62.
35. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91(9):3515-9.
36. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321-7.
37. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328-32.
38. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1):35-42.
39. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996;156(2):700-10.
40. Perricone MA, Claussen KA, Smith KA, Kaplan JM, Piraino S, Shankara S, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther. 2000;1(3):275-84.
41. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997;20(1):15-25.
42. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med. 1999;189(3):451-60.
43. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99(1):23-33.
44. Prabha S, Sharma B, Labhasetwar V. Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice. Cancer Gene Ther. 2012;19(8):530-7.
45. Zhang B, Jia F, Fleming MQ, Mallapragada SK. Injectable self-assembled block copolymers for sustained gene and drug co-delivery: an in vitro study. Int J Pharm. 2012;427(1):88-96.
46. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, Yun CO. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther. 2011;19(8):1558-68.
47. Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother. 2010;33(7):697-705.
48. Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012;189(5):2656-64.
49. Yang HG, Hu BL, Xiao L, Wang P. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther. 2011;18(5):370-80.
50. Seiler MP, Gottschalk S, Cerullo V, Ratnayake M, Mane VP, Clarke C, et al. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007;15(2):386-92.